ARCHIVES

An “insurgency” targets randomized trials, demands access to investigational drugs.

This article is from The Cancer Letter archive.

Vol. 31 No. 31 | August 5, 2005

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Trial Results Represent Culmination of Research, Klausner Tells House

March 19, 1999

In Brief: Interim Bill Keeps NCI Going Through Oct. 31; “Manual Fr Staging Of Cancer” Now Available

October 21, 1977

Conference Level For NCI Is 5.4% Over FY 1990

November 2, 1990

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

In Brief” McKenna New ACS President, Lemaistre President Elect; Michael Potter Wins Albert Lasker Award

November 23, 1984

BioSeek Awarded NIH SBIR For Compound Validation.

July 4, 2003